Peptidylarginine deiminase 4 overexpression resensitizes MCF-7/ADR breast cancer cells to adriamycin via GSK3β/p53 activation

BACKGROUND: Adriamycin (ADR) is widely used in the clinical chemotherapy against breast cancer. But its efficacy is strongly limited due to the acquisition of multidrug resistance (MDR). Therefore, acquisition of the resistance to ADR is still a major cause of chemotherapy failure in breast cancer p...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Qianqian, Song, Chao, Liu, Xiaoqiu, Qin, Hao, Miao, Lixia, Zhang, Xuesen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331075/
https://www.ncbi.nlm.nih.gov/pubmed/30666159
http://dx.doi.org/10.2147/CMAR.S191353

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331075/
https://www.ncbi.nlm.nih.gov/pubmed/30666159
http://dx.doi.org/10.2147/CMAR.S191353

Ejemplares similares